Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test sale cost 2810 AED
Fibroblast Growth Factor FGF2 Test sale cost 3020 AED Fibroblast Growth Factor FGF2 Test Cost 3,350 د.إ Original price was: 3,350 د.إ.3,020 د.إCurrent price is: 3,020 د.إ.
Immunohistochemistry PDL1 SP142 Test sale cost 2700 AED Immunohistochemistry PDL1 SP142 Test Cost 3,000 د.إ Original price was: 3,000 د.إ.2,700 د.إCurrent price is: 2,700 د.إ.
Sale!

Minimal Residual Disease MRD Monitoring for Multiple Myeloma Test Cost

Original price was: 3,120 د.إ.Current price is: 2,810 د.إ.

-10%

Minimal Residual Disease (MRD) monitoring for Multiple Myeloma is a highly sensitive test performed to detect the smallest number of myeloma cells remaining in the patient’s body after treatment. This advanced diagnostic approach allows for the precise assessment of the disease’s status, helping to tailor treatment plans more effectively and predict patient outcomes. MRD testing is particularly crucial in understanding the depth of response to therapy, guiding decisions on treatment continuation, modification, or cessation.

Performed at DNA Labs UAE, the MRD test for Multiple Myeloma utilizes cutting-edge technology to ensure accurate and reliable results. The cost of the test is set at 2810 AED, reflecting the sophisticated nature of the analysis and the detailed insights it provides into the patient’s condition. By opting for MRD monitoring at DNA Labs UAE, patients and healthcare providers can access crucial data to make informed decisions regarding multiple myeloma management and follow-up care strategies.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

MINIMAL RESIDUAL DISEASE MRD MONITORING FOR MULTIPLE MYELOMA Test

Test Cost: AED 2810.0

Test Components:

  • CD45
  • CD19
  • CD20
  • CD27
  • CD38
  • CD138
  • CD56
  • CD117
  • CD200
  • CD81
  • Kappa
  • Lambda

Sample Condition:

3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube. Mix thoroughly & Ship immediately at 18-22°C or at 2-8°C. DO NOT FREEZE. Following information is mandatory:

  • Sample time point (Chemotherapy time points)
  • Previous diagnostic immunophenotype report
  • Clinical History specially mention if patient is on anti-CD38 therapy
  • Original TRF
  • Date and time when sample was drawn
  • 1 or 2 unstained BMA smears to be made at source

Report Delivery:

Sample Daily by 9 am; Report 3 Working days

Method:

FLOW CYTOMETRY

Test Type:

Multiple Myeloma

Doctor:

Oncologist

Test Department:

FLOW CYTOMETRY

Pre Test Information:

Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History specially mention if patient is on anti-CD38 therapy; original TRF; Date and time when sample was drawn; 1 or 2 unstained BMA smears to be made at source.

Test Details:

Minimal residual disease (MRD) monitoring is a test used in the management of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. MRD testing is performed to assess the response to treatment and to detect any remaining cancer cells after treatment. The test involves analyzing a bone marrow or blood sample to identify and quantify the presence of residual cancer cells. MRD testing is highly sensitive and can detect cancer cells at very low levels, even when conventional tests cannot.

There are different methods used for MRD monitoring, including flow cytometry, next-generation sequencing (NGS), and polymerase chain reaction (PCR). These techniques allow for the detection of specific genetic abnormalities or markers associated with multiple myeloma. MRD monitoring is typically performed at various time points during and after treatment to evaluate the effectiveness of therapy and to guide treatment decisions.

A negative MRD result indicates a deeper response to treatment and may suggest a better prognosis. On the other hand, a positive MRD result indicates the presence of residual disease and may prompt further treatment adjustments or interventions.

Overall, MRD monitoring for multiple myeloma is an important tool in assessing treatment response and guiding treatment decisions. It provides valuable information to healthcare providers and helps in tailoring treatment plans for individual patients.

Test Name MINIMAL RESIDUAL DISEASE MRD MONITORING FOR MULTIPLE MYELOMA Test
Components *CD45 *CD19 *CD20 *CD27 *CD38 *CD138 *CD56 *CD117 *CD200 *CD81 *Kappa *Lambda
Price 2810.0 AED
Sample Condition 3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube. Mix thoroughly & Ship immediately at18-22?\u00f8C or at 2-8?\u00f8C. DO NOT FREEZE. Following information is mandatory:\nSample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History specially mention if patient is on anti-CD38 therapy; original TRF;Date and time when sample was drawn; 1 or 2 unstained BMA smears to be made at source.
Report Delivery Sample Daily by 9 am; Report 3 Working days
Method FLOW CYTOMETRY
Test type Multiple Myeloma
Doctor Oncologist
Test Department: FLOW CYTOMETRY
Pre Test Information Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History specially mention if patient is on anti-CD38 therapy; original TRF;Date and time when sample was drawn; 1 or 2 unstained BMA smears to be made at source.
Test Details

Minimal residual disease (MRD) monitoring is a test used in the management of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. MRD testing is performed to assess the response to treatment and to detect any remaining cancer cells after treatment.

The test involves analyzing a bone marrow or blood sample to identify and quantify the presence of residual cancer cells. MRD testing is highly sensitive and can detect cancer cells at very low levels, even when conventional tests cannot.

There are different methods used for MRD monitoring, including flow cytometry, next-generation sequencing (NGS), and polymerase chain reaction (PCR). These techniques allow for the detection of specific genetic abnormalities or markers associated with multiple myeloma.

MRD monitoring is typically performed at various time points during and after treatment to evaluate the effectiveness of therapy and to guide treatment decisions. A negative MRD result indicates a deeper response to treatment and may suggest a better prognosis. On the other hand, a positive MRD result indicates the presence of residual disease and may prompt further treatment adjustments or interventions.

Overall, MRD monitoring for multiple myeloma is an important tool in assessing treatment response and guiding treatment decisions. It provides valuable information to healthcare providers and helps in tailoring treatment plans for individual patients.

SKU: TEST-4823 Category:

Related products